Literature DB >> 24722443

Endothelin antagonists in diabetic nephropathy: back to basics.

Kiran Chandrashekar1, Luis A Juncos2.   

Abstract

Entities:  

Keywords:  cell signaling; chronic kidney disease; diabetic; endothelin antagonists; glomerulosclerosis; nephropathy; podocyte

Mesh：

Substances：

Year:  2014        PMID： 24722443      PMCID： PMC4005324          DOI： 10.1681/ASN.2014020174

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  18 in total

1.  Regional distribution of immunoreactive endothelin in porcine tissue: abundance in inner medulla of kidney.

Authors:  K Kitamura; T Tanaka; J Kato; T Eto; K Tanaka
Journal:  Biochem Biophys Res Commun       Date:  1989-05-30       Impact factor: 3.575

Review 2.  The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure.

Authors:  Donald E Kohan
Journal:  Curr Opin Nephrol Hypertens       Date:  2006-01       Impact factor: 2.894

3.  Elevated plasma endothelin in patients with diabetes mellitus.

Authors:  K Takahashi; M A Ghatei; H C Lam; D J O'Halloran; S R Bloom
Journal:  Diabetologia       Date:  1990-05       Impact factor: 10.122

4.  Effects of endothelin receptor antagonists on the progression of diabetic nephropathy.

Authors:  B Hocher; A Schwarz; D Reinbacher; J Jacobi; A Lun; F Priem; C Bauer; H H Neumayer; M Raschack
Journal:  Nephron       Date:  2001-02       Impact factor: 2.847

5.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

6.  Defining translational research: implications for training.

Authors:  Doris McGartland Rubio; Ellie E Schoenbaum; Linda S Lee; David E Schteingart; Paul R Marantz; Karl E Anderson; Lauren Dewey Platt; Adriana Baez; Karin Esposito
Journal:  Acad Med       Date:  2010-03       Impact factor: 6.893

7.  Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs.

Authors:  T F Lüscher; M Barton
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

8.  The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.

Authors:  Dick de Zeeuw; Blai Coll; Dennis Andress; John J Brennan; Hui Tang; Mark Houser; Ricardo Correa-Rotter; Donald Kohan; Hiddo J Lambers Heerspink; Hirofumi Makino; Vlado Perkovic; Yili Pritchett; Giuseppe Remuzzi; Sheldon W Tobe; Robert Toto; Giancarlo Viberti; Hans-Henrik Parving
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

Review 9.  Endothelin: 20 years from discovery to therapy.

Authors:  Matthias Barton; Masashi Yanagisawa
Journal:  Can J Physiol Pharmacol       Date:  2008-08       Impact factor: 2.273

10.  Avosentan for overt diabetic nephropathy.

Authors:  Johannes F E Mann; Damian Green; Kenneth Jamerson; Luis M Ruilope; Susan J Kuranoff; Thomas Littke; Giancarlo Viberti
Journal:  J Am Soc Nephrol       Date:  2010-02-18       Impact factor: 10.121
View more
  7 in total

1.  Association between Endothelin-1 Levels and Kidney Disease among Blacks.

Authors:  Casey M Rebholz; Jane L Harman; Morgan E Grams; Adolfo Correa; Daichi Shimbo; Josef Coresh; Bessie A Young
Journal:  J Am Soc Nephrol       Date:  2017-07-11       Impact factor: 10.121

2.  Plasma Endothelin-1 and Risk of Death and Hospitalization in Patients Undergoing Maintenance Hemodialysis.

Authors:  Ping Li; Insa M Schmidt; Venkata Sabbisetti; Maria Clarissa Tio; Alexander R Opotowsky; Sushrut S Waikar
Journal:  Clin J Am Soc Nephrol       Date:  2020-05-07       Impact factor: 8.237

3.  Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.

Authors:  Bauke Schievink; Dick de Zeeuw; Paul A Smink; Dennis Andress; John J Brennan; Blai Coll; Ricardo Correa-Rotter; Fan Fan Hou; Donald Kohan; Dalane W Kitzman; Hirofumi Makino; Hans-Henrik Parving; Vlado Perkovic; Giuseppe Remuzzi; Sheldon Tobe; Robert Toto; Jarno Hoekman; Hiddo J Lambers Heerspink
Journal:  Eur J Prev Cardiol       Date:  2015-07-30       Impact factor: 7.804

Review 4.  What is damaging the kidney in lupus nephritis?

Authors:  Anne Davidson
Journal:  Nat Rev Rheumatol       Date:  2015-11-19       Impact factor: 20.543

5.  Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner.

Authors:  Mohammed A Samad; Ui Kyoung Kim; Joshua J Kang; Qingen Ke; Peter M Kang
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

Review 6.  Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review.

Authors:  Noorain Ahmad; Harish Veerapalli; Chetan Reddy Lankala; Everardo E Castaneda; Afia Aziz; Amy G Rockferry; Pousette Hamid
Journal:  Cureus       Date:  2021-11-07

Review 7.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.